⚠ Evidence note: Mechanistic aging biology translates to human interventions slowly and unreliably; model-organism lifespan gains have repeatedly failed to transfer.
Circulating Senosome
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-03-11 — Communication breakdown: senescent cells in interorgan communication of aging.: cross-connection with cellular-senescence: Opinion piece reinforces that systemic SASP-plus-EV output from senescent cells is the substrate for the circulating senosome’s interorgan reach, framing blood-borne senescent-cell-derived mediators as the propagation channel for inflammaging between tissues. (novelty: 3)
- 2026-07-14 — A compendium of circulating biomarkers of senescence in humans: Insights on mechanistic impact across health domains and modulation by therapeutic interventions.: cross-connection with cellular-senescence: The compendium formalizes GDF15 and Activin A as the most consistent circulating SASP indices across human studies, giving the senosome blood-interface framing a concrete two-marker anchor for noninvasive senescence-burden readout. (novelty: 3)
- 2026-07-19 — The circulating senosome: Blood as the therapeutic interface of aging.: 2026 review introduces the ‘circulating senosome’ as a unifying composite of blood-borne aging mediators — SASP factors, extracellular vesicles, cytokines, lipids, metabolites, complement/coagulation proteins, autoantibodies, cell-free nucleic acids, and microbiome-derived products — framing blood as both biomarker compartment and therapeutic interface across hallmarks; synthesis only, no new primary data. [mechanism-plausible] (novelty: 3)
Open questions
Related
Contributing findings
The circulating senosome: Blood as the therapeutic interface of aging.
19-jul-2026
novelty 3
per-area 3
strengthens